Ekene Enemchukwu, MD, on underutilization of vaginal estrogen for GSM
April 15th 2025“Given the rates in epidemiologic studies and surveys showing that up to 70% of women are symptomatic, we were surprised to find that only 9% [filled] a prescription,” says Ekene Enemchukwu, MD, MPH, FACS, URPS.
How rBCG EAP could open up access for Anktiva in bladder cancer
April 11th 2025“I feel a lot of providers, with Antiva being available, have unfortunately reserved use of this great FDA-approved agent for BCG-unresponsive patients because of the supply issue with BCG," says Suzanne B. Merrill, MD, FACS.
How pre-URS tamsulosin use in pediatric patients may reduce repeat procedures
April 8th 2025“I would say the take-home message for this study is that prescribing tamsulosin for a week prior to an anticipated surgery that involves flexible ureteroscopy is a very simple practice that certainly is within standard of care within pediatric urology," says Kate H. Kraft, MD, MHPE, FACS, FAAP.
Expert discusses innovations in single-use ureteroscopes for stones
April 7th 2025"A lot of people are using [single-use ureteroscopes] nowadays, and part of it is because it really enhances our ability to provide guaranteed care, because we don't have to rely on the reusability of scopes," says Perry Xu, MD.
Naeem Bhojani, MD, discusses WATER III data on Aquablation vs enucleation for BPH
April 6th 2025"This study was an investigator initiated study, and what they wanted to do was a randomized trial for large prostates, so 80 to 180 grams, between Aquablation and prostate enucleation," says Naeem Bhojani, MD, FRCSC.
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
April 3rd 2025"We see the overall survival, whether it is [in] all-comers, in HRR gene mutation-positive patients, or in HRR gene [mutation]-negative patients or [those] who did not have mutations, the overall survival is about 45 to 47 months," says Neeraj Agarwal, MD, FACS.
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
April 1st 2025“If it is as efficacious as it looks, we will have more patients who are getting effective standard of care treatment, not needing to go on to further treatment, not having recurrences, [having decreased] morbidity from repeated resections, and saving bladders in the process," says Eugene B. Cone, MD.